PR
Pudhucode Radhakrishnan Kannan
About Pudhucode Radhakrishnan Kannan
Data last updated:
Pudhucode Radhakrishnan Kannan is a Director at Tenshi Pharmaceuticals Private Limited (since 2024), Director at Aurore Life Sciences Private Limited (since 2025) and Nominee Director at Naari Pharma Private Limited (since 2025), and holds 5 more current directorships. The companies operate in Financial Services, Pharma and Telecom. The 5 current companies with reported revenue have a combined latest revenue of ₹1,776 Cr; the largest is Tenshi Pharmaceuticals Private Limited at ₹1,071 Cr (FY 2024). Earlier, Pudhucode Radhakrishnan Kannan was a Whole-Time Director at Onesource Specialty Pharma Limited (2017–2024) and Director at Biolexis Private Limited (2022–2024) and 53 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 17 Jun 2024 | 2016 | ₹1,071 Cr (FY 2024) | Active | |
| Director | 13 Jan 2025 | 2016 | ₹471 Cr (FY 2025) | Active | |
| Nominee Director | 24 Jul 2025 | 1978 | ₹136 Cr (FY 2025) | Active | |
| Nominee Director | 30 Sep 2024 | 2007 | ₹81.13 Cr (FY 2025) | Active | |
| Director | 01 Jan 2025 | 2020 | ₹16.45 Cr (FY 2023) | Active | |
| Director | 19 Jan 2026 | 2026 | Active | ||
| Director | 05 Aug 2025 | 2025 | Active | ||
| Director | 19 Jul 2025 | 2025 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Whole-Time Director | 25 Mar 2017 | 2007 | ₹1,437 Cr (FY 2026) | Active | |
| Director | 17 Jan 2022 | 2022 | ₹1.87 Cr (FY 2025) | Active | |
| Designated Partner | 09 Feb 2011 | 2011 | ₹21.31 Cr (FY 2020) | Active | |
| Director | 08 Jul 2015 | 2007 | ₹9.52 Cr (FY 2025) | Amalgamated | |
| Director | 20 Aug 2012 | 2003 | ₹16.74 Cr (FY 2025) | Active | |
| Director | 31 Mar 2012 | 2010 | Amalgamated | ||
| Director | 02 Apr 2012 | 2002 | ₹5.03 Cr (FY 2025) | Active | |
| Director | 02 Apr 2012 | 2009 | ₹1.92 Cr (FY 2025) | Active | |
| Designated Partner | 19 Jun 2015 | 2015 | Strike Off | ||
| Director | 02 Apr 2012 | 2011 | Strike Off | ||
| Alternate Director | 01 Mar 2018 | 2016 | ₹12.50 Cr (FY 2017) | Amalgamated | |
| Director | 13 Feb 2017 | 2017 | ₹34.7 Lakh (FY 2018) | Dissolved (Liquidated) |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Pudhucode Radhakrishnan Kannan
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Pudhucode Radhakrishnan Kannan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pudhucode Radhakrishnan Kannan
Pudhucode Radhakrishnan Kannan currently holds 8 directorships: Tenshi Pharmaceuticals Private Limited (Director, since 17 Jun 2024, revenue ₹1,071 Cr (FY 2024)); Aurore Life Sciences Private Limited (Director, since 13 Jan 2025, revenue ₹471 Cr (FY 2025)); Naari Pharma Private Limited (Nominee Director, since 24 Jul 2025, revenue ₹136 Cr (FY 2025)); Quadgen Wireless Solutions Private Limited (Nominee Director, since 30 Sep 2024, revenue ₹81.13 Cr (FY 2025)); Brooks Steriscience Limited (Director, since 01 Jan 2025, revenue ₹16.45 Cr (FY 2023)); and 3 more.
Pudhucode Radhakrishnan Kannan was first appointed on 09 Feb 2011 as Designated Partner at Pronomz Ventures Llp. The most recent appointment on record is 19 Jan 2026 at Dvise Pharma Tech Private Limited.
The 5 current companies of Pudhucode Radhakrishnan Kannan that report revenue have a combined latest revenue of ₹1,776 Cr: Tenshi Pharmaceuticals Private Limited ₹1,071 Cr (FY 2024); Aurore Life Sciences Private Limited ₹471 Cr (FY 2025); Naari Pharma Private Limited ₹136 Cr (FY 2025); Quadgen Wireless Solutions Private Limited ₹81.13 Cr (FY 2025); Brooks Steriscience Limited ₹16.45 Cr (FY 2023).
Pudhucode Radhakrishnan Kannan held 55 earlier board appointments: Onesource Specialty Pharma Limited (Whole-Time Director, 25 Mar 2017 to 17 Jun 2024); Biolexis Private Limited (Director, 17 Jan 2022 to 17 Jun 2024); Pronomz Ventures Llp (Designated Partner, 09 Feb 2011 to 10 Jan 2021); Sequent Research Limited (Director, 08 Jul 2015 to 24 May 2017); Chayadeep Properties Private Limited (Director, 20 Aug 2012 to 27 Feb 2017); and 50 more.
The current boards of Pudhucode Radhakrishnan Kannan's companies include Shridhara Kela (Tenshi Pharmaceuticals Private Limited), Dilip Murthy Buddha (Aurore Life Sciences Private Limited), Pooja Toshniwal (Aurore Life Sciences Private Limited), Rajender Juvvadi Rao (Aurore Life Sciences Private Limited), Suresh Mudhunuri (Aurore Life Sciences Private Limited), Deepak Komaregowda (Naari Pharma Private Limited), among others.